Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000
- 3 February 2003
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 12 (4) , 327-334
- https://doi.org/10.1002/pds.809
Abstract
Purpose The aim of this study is to explore trends in primary care prescribing for chronic heart failure (CHF) over a 5‐year period (1996–2000). Methods This study consisted of repeated cross‐sectional surveys in a dynamic cohort from the Integrated Primary Care Information (IPCI) primary care database. The cohort comprised all patients aged ≥55 years with a CHF diagnosis and prescribed a cardiovascular medication during the study period. The point prevalence per calendar year was determined for each of the main drug groups used to treat CHF. Results The study population consisted of 3121 CHF patients. Small increases were seen in the percentage of CHF patients prescribed spironolactone (4.6%, 95% CI: 2.3–6.9%), β‐blockers (6.1%, 95% CI: 2.6–9.5%) and angiotensin II antagonists (6.8%, 95% CI: 5.1–8.6%) during the study period, while the prescribing of digoxin decreased (−4.4%, 95% CI: −8.2 to −0.7). Prescribing of diuretics (difference: −0.7% 95% CI: −2.7–4.2) and ACE inhibitors (difference: 4.0% 95% CI: −0.1–8.2%) remained unchanged. Conclusions Prescription of some drug groups for CHF increased. However, given the new scientific evidence that has emerged in past 15 years regarding CHF pharmacotherapy, the changes observed were less than expected. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Are angiotensin ii receptor blockers more efficacious than placebo in heart failure? implications of elite-2The American Journal of Cardiology, 2001
- Modern management of hypertension and heart failure: evidence and practiceHeart, 2000
- Improving patient outcomes in heart failure: evidence and barriersHeart, 2000
- Differences in drug treatment of chronic heart failure between European countriesEuropean Heart Journal, 1999
- Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?International Journal of Cardiology, 1997
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996
- Bridges between Health Care Research Evidence and Clinical PracticeJournal of the American Medical Informatics Association, 1995
- Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.BMJ, 1993
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987